ATE284870T1 - Antagonisten des vitronectin-receptors - Google Patents

Antagonisten des vitronectin-receptors

Info

Publication number
ATE284870T1
ATE284870T1 AT00961619T AT00961619T ATE284870T1 AT E284870 T1 ATE284870 T1 AT E284870T1 AT 00961619 T AT00961619 T AT 00961619T AT 00961619 T AT00961619 T AT 00961619T AT E284870 T1 ATE284870 T1 AT E284870T1
Authority
AT
Austria
Prior art keywords
antagonists
vitronectin receptor
vitronectin
receptor
Prior art date
Application number
AT00961619T
Other languages
English (en)
Inventor
Peter J Manley
William H Miller
Irene N Uzinskas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE284870T1 publication Critical patent/ATE284870T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00961619T 1999-09-07 2000-09-07 Antagonisten des vitronectin-receptors ATE284870T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15278099P 1999-09-07 1999-09-07
PCT/US2000/024514 WO2001017959A2 (en) 1999-09-07 2000-09-07 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE284870T1 true ATE284870T1 (de) 2005-01-15

Family

ID=22544416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961619T ATE284870T1 (de) 1999-09-07 2000-09-07 Antagonisten des vitronectin-receptors

Country Status (29)

Country Link
EP (1) EP1218005B1 (de)
JP (1) JP4685307B2 (de)
KR (1) KR100711170B1 (de)
CN (1) CN1236767C (de)
AR (1) AR025589A1 (de)
AT (1) ATE284870T1 (de)
AU (1) AU768918B2 (de)
BR (1) BR0013749A (de)
CA (1) CA2384671A1 (de)
CO (1) CO5200845A1 (de)
CZ (1) CZ2002822A3 (de)
DE (1) DE60016769T2 (de)
EG (1) EG24179A (de)
ES (1) ES2234658T3 (de)
GC (1) GC0000203A (de)
HK (1) HK1049110B (de)
HU (1) HUP0202710A3 (de)
IL (2) IL148325A0 (de)
MX (1) MXPA02002455A (de)
NO (1) NO322109B1 (de)
NZ (1) NZ517296A (de)
PE (1) PE20010582A1 (de)
PL (1) PL200404B1 (de)
PT (1) PT1218005E (de)
TR (1) TR200200614T2 (de)
TW (1) TWI255813B (de)
UY (1) UY26329A1 (de)
WO (1) WO2001017959A2 (de)
ZA (1) ZA200201780B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
RU2367661C2 (ru) * 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
EP2956455B1 (de) 2013-02-13 2017-05-17 Novartis AG Als ip-rezeptor-agonisten wirkende heterocyclische verbindungen
CN108675954A (zh) * 2018-04-03 2018-10-19 爱斯特（成都）生物制药股份有限公司 2-氨基-3-羟甲基吡啶的一种制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
IL125034A0 (en) * 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
CO5080762A1 (es) * 1998-03-10 2001-09-25 Smithkline Beechman Corp Antagonistas de receptor de vitronectina
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
KR20020027624A (ko) 2002-04-13
EG24179A (en) 2008-09-28
EP1218005B1 (de) 2004-12-15
KR100711170B1 (ko) 2007-04-27
DE60016769D1 (de) 2005-01-20
IL148325A0 (en) 2002-09-12
NO322109B1 (no) 2006-08-14
PL354176A1 (en) 2003-12-29
EP1218005A2 (de) 2002-07-03
CO5200845A1 (es) 2002-09-27
HK1049110B (zh) 2005-07-22
CN1236767C (zh) 2006-01-18
PL200404B1 (pl) 2009-01-30
DE60016769T2 (de) 2005-11-24
CA2384671A1 (en) 2001-03-15
TR200200614T2 (tr) 2002-07-22
HUP0202710A3 (en) 2003-06-30
CZ2002822A3 (cs) 2002-07-17
IL148325A (en) 2007-06-03
AR025589A1 (es) 2002-12-04
PT1218005E (pt) 2005-05-31
HUP0202710A2 (hu) 2002-12-28
WO2001017959A2 (en) 2001-03-15
NO20021113D0 (no) 2002-03-06
AU7354300A (en) 2001-04-10
ZA200201780B (en) 2003-05-28
UY26329A1 (es) 2001-07-31
AU768918B2 (en) 2004-01-08
NZ517296A (en) 2003-11-28
JP2003508516A (ja) 2003-03-04
WO2001017959A3 (en) 2001-05-10
MXPA02002455A (es) 2002-07-02
CN1377269A (zh) 2002-10-30
JP4685307B2 (ja) 2011-05-18
TWI255813B (en) 2006-06-01
EP1218005A4 (de) 2002-10-09
ES2234658T3 (es) 2005-07-01
HK1049110A1 (en) 2003-05-02
GC0000203A (en) 2006-03-29
PE20010582A1 (es) 2001-06-23
NO20021113L (no) 2002-05-03
BR0013749A (pt) 2003-06-10

Similar Documents

Publication Publication Date Title
ATE235467T1 (de) Antagonisten des vitronectin-rezeptors
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
ATE312089T1 (de) Vitronektin rezeptor antagonisten
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20016053L (no) IL-8 reseptor-antagonister
NO20016052L (no) IL-8-reseptor-antagonister
ATE277043T1 (de) Vitronectin rezeptor antagonist
NO20020644D0 (no) Nye integrinreseptor-antagonister
ATE284870T1 (de) Antagonisten des vitronectin-receptors
DK1180028T3 (da) IL-8-receptorantagonister
NO20015237L (no) Integrinreseptor-antagonister
NO20015774D0 (no) IL-8 reseptorantagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
DK1218005T3 (da) Vitronectinreptorantagonister
PL352222A1 (en) Antagonists of the il-8 receptor
NO20016065L (no) IL-8-reseptor-antagonister
SE0003996D0 (sv) Receptorantagonister
DK1131291T3 (da) 4-aroyl-piperidin-CCR-3-receptorantagonister III

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218005

Country of ref document: EP

REN Ceased due to non-payment of the annual fee